NEW YORK (GenomeWeb) – MDxHealth announced today that its ConfirmMDx for Prostate Cancer screening test has been included in the US 2016 National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer screening.

"Tests that improve specificity in the post-biopsy state — including 4Kscore, PHI, percent free PSA, PCA3, and ConfirmMDx — should be considered in patients thought to be higher risk despite a negative prostate biopsy," the NCCN guidelines now say.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.